TĂNG ÁP LỰC ĐỘNG MẠCH PHỔI VÀ MỘT SỐ YẾU TỐ LIÊN QUAN Ở BỆNH NHÂN XƠ CỨNG BÌ HỆ THỐNG

Abstract

Systemic scleroderma (SSc) is a rare connective tissue disorder. Although there have been many advances in diagnosis and treatment, systemic scleroderma still causes a significant deterioration in quality. life and high mortality rate. Lung damage is very common in SSc patients. Pulmonary hypertension is one of the two main manifestations of lung damage in SSc patients and is the main cause of death in this group of patients.¹ Research objective: Describe clinical and paraclinical symptoms of pulmonary arterial hypertension (PAH) in scleroderma patients and comment on some related factors. Research subjects and methods: descriptive, cross-sectional study of 75 patients diagnosed with scleroderma according to ACR/ EULAR 2013 criteria who came for medical examination or inpatient treatment at Bach Mai Hospital from September 2023 to October. August 2024. Results: The rate of PAH in SSc disease is 47.95%. Patients with higher NYHA dyspnea and increased pulse have a higher rate of PAH with p<0.05. Patients with dry cough have a 2.7 times higher risk of PAH (95% CI: 1.1-7.0; p=0.035), and with palpitations, the risk of PAH is 3.7 times higher (95% CI): 1.4-10.1; p=0.008), subjects with increased CRP index had pulmonary hypertension 7.6 times higher than subjects with normal CRP index (95% CI: 2.4-24.3; p<0.001). Conclusion: The incidence of PAH in patients with SSc in our study is quite high, and the risk of PAH in groups of subjects with clinical symptoms of dyspnea, dry cough, palpitations, rapid pulse, and increased CRP is increased